Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

The emergence of translational epidemiology: from scientific discovery to population health impact.

Khoury MJ, Gwinn M, Ioannidis JP.

Am J Epidemiol. 2010 Sep 1;172(5):517-24. doi: 10.1093/aje/kwq211. Epub 2010 Aug 5.

2.

Assessment of improved prediction beyond traditional risk factors: when does a difference make a difference?

Janssens AC, Khoury MJ.

Circ Cardiovasc Genet. 2010 Feb;3(1):3-5. doi: 10.1161/CIRCGENETICS.110.938092. No abstract available.

3.

A catalogue of reporting guidelines for health research.

Simera I, Moher D, Hoey J, Schulz KF, Altman DG.

Eur J Clin Invest. 2010 Jan;40(1):35-53. doi: 10.1111/j.1365-2362.2009.02234.x. Review.

PMID:
20055895
4.

Assessment of claims of improved prediction beyond the Framingham risk score.

Tzoulaki I, Liberopoulos G, Ioannidis JP.

JAMA. 2009 Dec 2;302(21):2345-52. doi: 10.1001/jama.2009.1757. Review.

PMID:
19952321
5.

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D.

PLoS Med. 2009 Jul 21;6(7):e1000100. doi: 10.1371/journal.pmed.1000100. Epub 2009 Jul 21.

6.

Prognosis and prognostic research: application and impact of prognostic models in clinical practice.

Moons KG, Altman DG, Vergouwe Y, Royston P.

BMJ. 2009 Jun 4;338:b606. doi: 10.1136/bmj.b606. No abstract available.

PMID:
19502216
7.

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.

Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council.

Circulation. 2009 May 5;119(17):2408-16. doi: 10.1161/CIRCULATIONAHA.109.192278. Epub 2009 Apr 13. Erratum in: Circulation. 2009 Jun 30;119(25):e606. Hong, Yuling [added].

8.

Genome-based prediction of common diseases: methodological considerations for future research.

Janssens AC, van Duijn CM.

Genome Med. 2009 Feb 18;1(2):20. doi: 10.1186/gm20.

9.

STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement.

Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N; STrengthening the REporting of Genetic Association Studies.

PLoS Med. 2009 Feb 3;6(2):e22. doi: 10.1371/journal.pmed.1000022.

10.

STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK... and CONSORT: for whom does the guideline toll?

Vandenbroucke JP.

J Clin Epidemiol. 2009 Jun;62(6):594-6. doi: 10.1016/j.jclinepi.2008.12.003. Epub 2009 Jan 31. No abstract available.

PMID:
19181482
11.
12.

Almost all articles on cancer prognostic markers report statistically significant results.

Kyzas PA, Denaxa-Kyza D, Ioannidis JP.

Eur J Cancer. 2007 Nov;43(17):2559-79. Epub 2007 Nov 5. Review.

PMID:
17981458
13.

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.

Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative.

PLoS Med. 2007 Oct 16;4(10):e297. Review.

14.

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative.

PLoS Med. 2007 Oct 16;4(10):e296. Review.

15.

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS.

Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12.

PMID:
17569110
16.
17.

Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect.

Kyzas PA, Denaxa-Kyza D, Ioannidis JP.

J Natl Cancer Inst. 2007 Feb 7;99(3):236-43.

PMID:
17284718
18.

REporting recommendations for tumor MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Nat Clin Pract Urol. 2005 Aug;2(8):416-22.

PMID:
16482653
19.

Reporting recommendations for tumor marker prognostic studies.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

J Clin Oncol. 2005 Dec 20;23(36):9067-72. Epub 2005 Sep 19. No abstract available.

PMID:
16172462
20.

Selective reporting biases in cancer prognostic factor studies.

Kyzas PA, Loizou KT, Ioannidis JP.

J Natl Cancer Inst. 2005 Jul 20;97(14):1043-55.

PMID:
16030302

Supplemental Content

Support Center